Left ventricular assist devices in heart failure

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 5, 2012, Pages 649-656

  Kilic, Ahmet ^a   Ailawadi, Gorav ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

bridge to transplant; destination therapy; heart failure; mechanical circulatory support; ventricular assist device

Indexed keywords

ADRENAL DISEASE; ANTICOAGULATION; AORTA BALLOON; ARTERIAL THROMBOEMBOLISM; BLEEDING; CARDIOGENIC SHOCK; CLINICAL TRIAL (TOPIC); COMORBIDITY; DATA BASE; DIABETES MELLITUS; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMOLYSIS; HOSPITALIZATION; HUMAN; HYPERTENSION; INFECTION; LEFT VENTRICULAR ASSIST DEVICE; LIVER DYSFUNCTION; LUNG DISEASE; MENTAL DISEASE; MINIMAL BRAIN DYSFUNCTION; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; MYOCARDITIS; ORGAN PERFUSION; PERICARDIAL DISEASE; PERIPHERAL VASCULAR DISEASE; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SOCIAL STATUS; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE;

BIOCOMPATIBLE MATERIALS; DEVICE APPROVAL; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; SURVIVAL RATE; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84861863341     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.17     Document Type: Review

References (29)

1. Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123(4), e18-e209 (2011).
2. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J. Am. Coll. Cardiol. 52(6), 428-434 (2008).
3. Fosb oslash;l EL, Gislason GH, Poulsen HE et al. Prognosis in heart failure and the value of {beta}-blockers are altered by the use of antidepressants and depend on the type of antidepressants used. Circ. Heart Fail. 2(6), 582-590 (2009).
4. Rose EA, Gelijns AC, Moskowitz AJ et al.; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345(20), 1435-1443 (2001).
5. Hogness JR, Blumenthal D, Christopherson LK et al. The artificial heart program: current status and history, In: The Artificial Heart: Prototypes, Policies, and Patients. Hogness JR, Van Antwerp M (Eds). National Academy Press, Washington, DC, US 14-25 1991
6. Miller LW, Pagani FD, Russell SD et al.; HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N. Engl. J. Med. 357(9), 885-896 (2007).
7. Slaughter MS, Rogers JG, Milano CA et al.; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med. 361(23), 2241-2251 (2009).
8. Fang JC. Rise of the machines - left ventricular assist devices as permanent therapy for advanced heart failure. N. Engl. J. Med. 361(23), 2282-2285 (2009).
9. Holman WL, Kormos RL, Naftel DC et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J. Heart Lung Transplant. 28(1), 44-50 (2009).
10. Kirklin JK, Naftel DC, Kormos RL et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J. Heart Lung Transplant. 30(2), 115-123 (2011).
11. Starling RC, Naka Y, Boyle AJ et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J. Am. Coll. Cardiol. 57(19), 1890-1898 (2011).
12. Moazami N, Sun B, Feldman D. Stable patients on left ventricular assist device support have a disproportionate advantage: time to re-evaluate the current UNOS policy. J. Heart Lung Transplant. 30(9), 971-974 (2011).
13. Williams ML, Trivedi JR, McCants KC et al. Heart transplant vs left ventricular assist device in heart transplant-eligible patients. Ann. Thorac. Surg. 91(5), 1330-1333; discussion 1333 (2011).
14. Zimpfer D, Zrunek P, Roethy W et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J. Thorac. Cardiovasc. Surg. 133(3), 689-695 (2007).
15. Nair PK, Kormos RL, Teuteberg JJ et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. J. Heart Lung Transplant. 29(2), 201-208 (2010).
16. Etz CD, Welp HA, Tjan TD et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann. Thorac. Surg. 83(5), 1697-1705 (2007).
17. Slaughter MS. Will destination therapy be limited to large transplant centers? Tex. Heart Inst. J. 37(5), 562-564 (2010).
18. Adamson RM, Stahovich M, Chillcott S et al. Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device: a community hospital experience. J. Am. Coll. Cardiol. 57(25), 2487-2495 (2011).
19. Lietz K, Long JW, Kfoury AG et al. Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. Circ. Heart Fail. 2(1), 3-10 (2009).
20. Pamboukian SV, Tallaj JA, Brown RN et al. Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol. J. Heart Lung Transplant. 30(8), 879-887 (2011).
21. Brush S, Budge D, Alharethi R et al. End-of-life decision making and implementation in recipients of a destination left ventricular assist device. J. Heart Lung Transplant. 29(12), 1337-1341 (2010).
22. Mountis MM, Starling RC. Management of left ventricular assist devices after surgery: bridge, destination, and recovery. Curr. Opin. Cardiol. 24(3), 252-256 (2009).
23. Slaughter MS. Long-term continuous flow left ventricular assist device support and end-organ function: prospects for destination therapy. J. Card. Surg. 25(4), 490-494 (2010).
24. Russell SD, Rogers JG, Milano CA et al.; HeartMate II Clinical Investigators. Renal and hepatic function improve in advanced heart failure patients during continuousflow support with the HeartMate II left ventricular assist device. Circulation 120(23), 2352-2357 (2009).
25. Kamdar F, Boyle A, Liao K, Colvin-Adams M, Joyce L, John R. Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients. J. Heart Lung Transplant. 28(4), 352-359 (2009).
26. Radovancevic B, Vrtovec B, de Kort E, Radovancevic R, Gregoric ID, Frazier OH. End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J. Heart Lung Transplant. 26(8), 815-818 (2007).
27. Lamarche Y, Kearns M, Josan K et al. Successful weaning and explantation of the Heartmate II left ventricular assist device. Can. J. Cardiol. 27(3), 358-362 (2011).
28. Cohn WE, Gregoric ID, Radovancevic B, Frazier OH. A felt plug simplifies left ventricular assist device removal after successful bridge to recovery. J. Heart Lung Transplant. 26(11), 1209-1211 (2007).
29. Hunt SA, Baker DW, Chin MH et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J. Heart Lung Transplant. 21(2), 189-203 (2002).